- 1.
Universitetssykehus Nord-Norge. Nasjonal behandlingstjeneste for avansert trombocyttimmunologi. https://unn.no/fag-og-forskning/nasjonal-behandlingstjeneste-for-avansert-trombocyttimmunologi Lest 9.4.2021.
- 2.
Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710–5. [PubMed][CrossRef]
- 3.
Warkentin TE, Sheppard JA, Sigouin CS et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108: 2937–41. [PubMed][CrossRef]
- 4.
Marchetti M, Zermatten MG, Bertaggia Calderara D et al. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med 2021; 10: 683. [PubMed][CrossRef]
- 5.
Warkentin TE, Sheppard JI, Heels-Ansdell D et al. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest 2013; 144: 848–58. [PubMed][CrossRef]
- 6.
Lo GK, Juhl D, Warkentin TE et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759–65. [PubMed][CrossRef]
- 7.
Cuker A, Gimotty PA, Crowther MA et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120: 4160–7. [PubMed][CrossRef]
- 8.
Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15: 2099–114. [PubMed][CrossRef]
- 9.
Greinacher A, Holtfreter B, Krauel K et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118: 1395–401. [PubMed][CrossRef]
- 10.
Hursting MJ, Pai PJ, McCracken JE et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134: 774–80. [PubMed][CrossRef]
- 11.
Everett BM, Yeh R, Foo SY et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007; 83: 592–7. [PubMed][CrossRef]
- 12.
Brodard J, Kremer Hovinga JA, Fontana P et al. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost 2021; 19. doi: 10.1111/jth.15262. [PubMed][CrossRef]
- 13.
Patell R, Khan AM, Bogue T et al. Heparin induced thrombocytopenia antibodies in Covid-19. Am J Hematol 2020; 95. doi: 10.1002/ajh.25935. [PubMed][CrossRef]
- 14.
Schultz NH, Sørvoll IH, Michelsen AE et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384. doi: 10.1056/NEJMoa2104882. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.
Grovt estimat
16.04.2021Takk for veldig interessant og spennende artikkel! Jeg har en liten kommentar til utsagnet "Ut ifra internasjonale tall på vaksinerte og antall rapporterte tilfeller synes risikoen svært liten, men tallene fra Norge gir et foreløpig grovt estimat på ca. 1 per…